Targets › ACVR2B
2 programs from 2 companies in 3 trials: 3 Phase 2; Metabolic and endocrine, Neurology; next expected readout Jan 2027.
Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH…. (UniProt, Q13705)
Open in Phaseline: the race on ACVR2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Bimagrumab (LY3985863) Activin receptor type-2B antagonist | ACVR2B | Phase 2 | Obesity | Jan 2027 |
| Keros Therapeutics | KER-065 Activin type IIB receptor (ActR2B) ligand trap; inhibits myostatin and ActA signaling | ACVR2B | Phase 2 | Duchenne Muscular Dystrophy | Aug 2028 |
Obesity (2) Duchenne Muscular Dystrophy (1)
mixed (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.